Navigation Links
PharmaVentures Appoints Andy Smith as Head of Corporate Finance

OXFORD, England, October 4, 2011 /PRNewswire/ --

PharmaVentures today announced the appointment of Andy Smith as Head of Corporate Finance to significantly enhance Pharmaventures' advisory capabilities and offerings to the global healthcare and investment communities.

Fintan Walton, PhD, PharmaVentures' Chief Executive Office says "We are delighted to welcome Andy to PharmaVentures.  He brings a wealth of investment management experience and has also worked extensively across R&D and marketing in the healthcare sector. At PharmaVentures we are increasingly providing more investment bank style services to help our clients with their dealmaking and Andy's addition to PharmaVentures will therefore be of great benefit."

Andy has a PhD in molecular Biology and an MBA in International Marketing.  He has previously worked with Investment Managers 3i, Schroders Plc and AXA Framlington.  In 2007 he was awarded the techmark Technology Fund Manager of the year.  Since 2011 Andy has written a regular weekly column; Stockwatch, in Scrip and has lectured on healthcare valuations and modeling at the University of Cambridge for the last six years.

PharmaVentures Limited ( is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevision produces the highly popular PharmaDeals® range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

For further information
Fintan Walton, CEO

SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
2. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
3. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
4. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
5. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
6. Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PrimeraDx Appoints Albert A. Luderer to its Board of Directors
9. Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ... Dr. Norman C.W. Wong to its Board of ... comes to Zenith with a wealth of experience as co-founder ... molecular biology. --> --> ... Zenith Epigenetics, board of directors. Zenith,s long standing expertise in ...
(Date:11/30/2015)... 2015  Champions Oncology, Inc. (CSBR), engaged in the ... the development and use of oncology drugs, today announced ... be presenting at the LD MICRO Investor Conference on ... (PST).  The conference, held at the Luxe Sunset Bel ... , will feature 200 small/micro-cap companies and is expected ...
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, 2015 ... in Vienna, Austria to be ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") ... its Internet-delivered NovaVision Therapy Suite at the 3rd European ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):